ArticleBMJ case reports2023

Refractory pembrolizumab immunotherapy-related colitis requiring biological therapy in an inactive HBcAb carrier.

Nidaa Rasheed et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.